These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7991724)

  • 1. Effect of the placebo control condition in neuroendocrine challenge studies.
    Thompson PA; Maes M; Meltzer HY
    Psychiatry Res; 1994 Jun; 52(3):317-26. PubMed ID: 7991724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine challenges in the diagnosis of depressive disorders.
    López-Ibor JJ; Saiz-Ruiz J; Moral Iglesias L
    Br J Psychiatry Suppl; 1989 May; (4):73-6. PubMed ID: 2605013
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
    Kolakowska T; Gelder M; Fraser S
    Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine response to 5-hydroxytryptophan in seasonal affective disorder.
    Jacobsen FM; Sack DA; Wehr TA; Rogers S; Rosenthal NE
    Arch Gen Psychiatry; 1987 Dec; 44(12):1086-91. PubMed ID: 3500688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine response to L-5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children.
    Ryan ND; Birmaher B; Perel JM; Dahl RE; Meyer V; al-Shabbout M; Iyengar S; Puig-Antich J
    Arch Gen Psychiatry; 1992 Nov; 49(11):843-51. PubMed ID: 1444721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement.
    Curtis VA; Wright P; Reveley A; Kerwin R; Lucey JV
    Br J Psychiatry; 1995 May; 166(5):642-6. PubMed ID: 7620750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced growth hormone and prolactin responses in schizophrenia research.
    Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients.
    Abel KM; O'Keane V; Murray RM
    Br J Psychiatry; 1996 Jan; 168(1):57-60. PubMed ID: 8770429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects.
    Kleinman JE; Weinberger DR; Rogol A; Shiling DJ; Mendelson WB; Davis GC; Bunney WE; Wyatt RJ
    Psychiatry Res; 1982 Aug; 7(1):1-7. PubMed ID: 6127744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine findings in the schizophrenias.
    Garver DL
    Endocrinol Metab Clin North Am; 1988 Mar; 17(1):103-9. PubMed ID: 2897906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
    Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
    Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interest of 5-hydroxytryptophan (5-HTP) as a neuroendocrine marker in depressive illness. A negative report.
    Ansseau M; Doumont A; Thiry D; Geenen V; Legros JJ
    Acta Psychiatr Belg; 1983; 83(1):50-6. PubMed ID: 6604395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
    Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
    Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postsynaptic serotonergic activity in depressive patients: evaluation of the neuroendocrine strategy.
    Westenberg HG; van Praag HM; de Jong JT; Thijssen JH
    Psychiatry Res; 1982 Dec; 7(3):361-71. PubMed ID: 6984515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin response to buspirone is not impaired in drug-naïve first episode patients with major depressive disorder.
    Cubała WJ; Landowski J
    J Affect Disord; 2014 Jan; 152-154():468-73. PubMed ID: 24035672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone response to 5-HTP.
    Meltzer HY; Tricou BJ; Robertson A; Lowy M
    Psychiatry Res; 1983 Oct; 10(2):151-2. PubMed ID: 6606814
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients.
    Shapira B; Reiss A; Kaiser N; Kindler S; Lerer B
    J Affect Disord; 1989; 16(1):1-4. PubMed ID: 2521644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction.
    Lerer B; Ran A; Blacker M; Silver H; Weller MP; Drummer D; Ebstein B; Calev A
    Schizophr Res; 1988; 1(6):405-10. PubMed ID: 3154528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.